ZIVO · Zivo Bioscience, Inc.
$0.67
At close · Nov 27
Going-concern doubt
— flagged Nov 14, 2025
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the financial statements are issued.”View the 10-Q filed Nov 14, 2025
Market Cap
$16.53M
Shares
3.89M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$157.22K
+468.6%
FY2024
Net Income
-$13.38M
-72.1%
FY2024
Gross Margin
31.14%
-10.8pp
FY2024
Operating Margin
-8498.85%
+17768.8pp
FY2024
Diluted EPS
-$4.23
+8%
FY2024
Operating Cash Flow
-$4.31M
+25.6%
FY2024
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $209.03K | $157.22K | $27.65K | $0 | $0 | $20K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $103.89K | $82.73K | |
| $142.82K | $108.27K | $16.04K | $0 | — | — | — | — | — | — | — | — | $0 | $0 | $138.25K | $51.81K | |
| $66.21K | $48.95K | $11.61K | $0 | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | 31.14% | 41.99% | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $3.7M | $3.13M | $1.38M | $2.24M | $1.95M | $3.75M | $2.31M | $2.81M | $2.38M | $788.97K | $1.03M | $1.97M | $1.02M | $677.49K | $377.89K | $395.57K | |
| $4.83M | $10.28M | $5.9M | $6.49M | $6.69M | $4.82M | $4.08M | $1.35M | $2.13M | $832.24K | $963.3K | $1.04M | $1.19M | $938.2K | $603.1K | $1.24M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | $967 | $967 | $966 | |
| — | — | — | — | $0 | $0 | $0 | $0 | $18.75K | $25K | $25K | $25K | $19.45K | $73.84K | $91.43K | — | |
| $8.52M | $13.41M | $7.27M | $8.73M | $8.65M | $8.58M | $8.35M | $6.13M | $6.33M | $3.49M | — | — | — | $2.08M | $2.04M | $4.14M | |
| — | — | — | — | — | — | — | — | — | $3.49M | $3.06M | $5.15M | $3.11M | $2.08M | — | — | |
| -$8.46M | -$13.36M | -$7.26M | -$8.73M | -$8.65M | -$8.56M | -$8.35M | -$6.13M | -$6.33M | -$3.49M | -$3.06M | -$5.15M | -$3.11M | -$2.08M | -$1.94M | -$4.06M | |
| — | -8498.85% | -26267.67% | — | — | -42778.38% | — | — | — | — | — | — | — | — | -1865.71% | -4909.09% | |
| — | — | — | — | -$8.65M | -$8.56M | -$8.35M | -$6.13M | -$6.31M | -$3.47M | -$3.03M | -$5.13M | -$3.09M | -$2.01M | -$1.85M | — | |
| — | — | $23.79K | $13.32K | $44.68K | $97.63K | — | — | — | -$35.49K | -$2400 | $515.61K | -$441.48K | -$141.73K | -$47.11K | -$13.96K | |
| — | — | — | -$13.32K | -$110.76K | -$550.05K | -$3.16M | -$8.5M | -$3.71M | -$2.57M | -$2.73M | — | — | -$1.17M | -$793.3K | -$3.06M | |
| -$8.49M | -$13.38M | -$7.78M | -$8.75M | -$8.76M | -$9.11M | -$11.51M | -$14.64M | -$10.04M | -$6.06M | -$5.79M | $680.81K | -$10.1M | -$3.25M | -$2.73M | -$7.12M | |
| — | -8513.44% | -28127.25% | — | — | -45528.64% | — | — | — | — | — | — | — | — | -2629.3% | -8609.82% | |
| USD/shares | -$2.13 | -$4.23 | -$4.60 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | — | — | — | — | 67.7M | 46.07M | 26.11M | 23.21M | 22.31M | 21.82M | 20.89M | 18.7M | 16.9M | — | — |
| shares | — | 3.17M | 1.69M | — | — | 67.7M | 46.07M | 26.11M | 23.21M | 22.31M | 21.82M | 30.37M | 18.7M | 16.9M | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Coverage backlog: 40 eligible filings and 0 covenant artifacts have no current-version terminal extraction result. This includes untouched sources and sources on the retry ladder.
No terminal debt extraction result is available yet; this is not evidence that the company has no debt.